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(18FDG PET/CT) may not be a viable
biomarker in Pompe disease
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Abstract
Background: Pompe disease (PD) is an autosomal recessive, lysosomal storage disease due to a mutation of the acid
α-glucosidase (GAA) gene. In adult patients, PD is characterized by slowly progressive limb-girdle and trunk myopathy and
restrictive respiratory insufficiency. Enzyme replacement therapy (ERT) is available, improving or stabilizing muscle-function
in some and slowing deterioration in other patients. Unfortunately, there is no biomarker available to indicate therapeutic
efficacy and/or disease activity. Whole body MRI depicts all skeletal muscles demonstrating foci of atrophic muscles, i.e.,
late and irreversible pathological changes. Any method indicating the localizations of increased muscle glycogen storage,
muscle inflammation and/or degradation could possibly help identifying newly afflicted tissue and may be of prognostic
value. We therefore investigated 2-deoxy-2-[18]fluoro-D-glucose (FDG) PET, a biomarker for glucose-metabolism, as a tool
to evaluate disease activity and prognosis in PD.
Methods: In a pilot study, we investigated four patients by FDG dynamic PET/CT while on ERT. One patient had FDG-
PET/CT twice, before and after 12 months on ERT. Dynamic FDG-PET/CT quantifies the metabolic rate of glucose
utilisation in mg/ml/min. MRI was performed in parallel with pelvic and thigh muscles semi-quantitatively scored for
atrophy and disease-activity.
Results: None of the muscles analysed showed a focally increased FDG-uptake. Thus, quantification of muscle glucose
metabolism could not be calculated. However, increased FDG-uptake, i.e., increased glucose utilisation, was observed in
the respiratory muscles of one patient with severe, restrictive respiratory failure. In contrast, specific MRI sequences
showed oedematous as well as atrophic muscle areas in PD.
Conclusions: Our pilot study demonstrates that FDG-uptake does not correlate with glycogen storage in vivo. In contrast,
MRI is an excellent tool to demonstrate the extent of muscle involvement. Specific MRI sequences may even demonstrate
early changes possibly allowing prognostic predictions or localization of early stages of PD.
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Background
Pompe disease (OMIM 232300) or glycogenosis type 2 is
a lysosomal storage disease characterized by a mutation of
the acid α-glucosidase (GAA) gene. Pompe disease (PD) is
inherited in an autosomal recessive mode. Manifestations
of PD in adult patients are a myopathy of limb-girdle and
trunk muscles, with restrictive respiratory insufficiency as
a possible complication. The disease is chronic and slowly
progressive with some patients becoming wheel-chair-
bound and respirator-dependent. The available enzyme re-
placement therapy effectively improves or stabilizes
muscle function in some and slows deterioration of the
disease in other patients [1, 2].
The phenotype/genotype correlation is poor and many
patients harbour private mutations. Thus, genotyping is
unable to predict the clinical course of an individual pa-
tient [3]. Clinical monitoring, i.e., follow-up of the indi-
vidual patient, relies mainly either on semi-quantitative
analysis of muscle function, like 6-min walk test, quick
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motor function test [4] or magnetic resonance tomo-
graphic imaging (MRI) of limb-girdle, paravertebral and
thighs musculature and sometimes proximal arm mus-
culature, or in rare cases, repeated muscle biopsies. Re-
spiratory function is evaluated by lung function testing
[forced expiratory vital capacity (FVC) and vital capacity
(VC)], both while seated and supine. However, these
clinical evaluations are flawed by a high intra- and inter-
observer variation, as is the case for functional testing
[6-min walk test [5, 6] and quick motor function test [4].
In addition, the test-results vary depending on the pa-
tient’s sex, age and day-to-day state of health. A reliable
positive predictive result is therefore difficult to achieve
and intra-individual variability is high. Due to the lack of
more sensitive and accurate measurements, the 6-min
walk test is defined as the gold-standard and has been
used in clinical studies for the evaluation of motor func-
tion in adult patients with PD [3, 7].
Biochemical parameters, i.e., muscle enzymes like
aspartate aminotransferase/glutamat-pyruvat-transaminase
(AST/GOT), alanine aminotransferase/glutamat-oxalacetat-
transaminase (ALT/GPT), creatinine-kinase (CK) or lactate
dehydrogenase (LDH) are non-specifically increased in PD
and fail to correlate with disease severity or activity. The
glucose tetra-saccharide, Glcalpha1-6Glcalpha1-4glcalpha1-
4Glc (Glc(4)), is a glycogen-derived limit dextrin that corre-
lates with the extent of glycogen accumulation in skeletal
muscle. A retrospective analysis of clinical records of 208
patients evaluated for PD by this approach showed Glc(4)
having 94% sensitivity and 84% specificity for the diagnosis
of PD. However, while indicating the overall disease burden,
Glc(4) provided no information on the location and distri-
bution of excess glycogen accumulation [8]. In addition
Glc(4) excretion in adult-onset PD is low and ERT-induced
declines may be very small [8].
MRI imaging demonstrates the distribution pattern of
muscular atrophy, compensatory muscular hypertrophy
and vacuolised muscle fibres. A study with 34 adult-onset
PD patients compared whole body muscle MRI using
T1w and 3-point Dixon imaging of thighs and the lower
trunk region to a wide range of functional scales. This
comparison demonstrated a strong correlation between
muscle strength, muscle functional scales and the degree
of muscle fatty replacement in muscle MRI. In addition,
muscle MRI detected mild degree of fatty replacement in
para-spinal muscles in pre-symptomatic patients [9].
Others used either quantitative proton-density fat-fraction
(PDFF) whole-body MRI or quantitative MRI in late-onset
PD and compared the results with manual muscle testing.
According to their results, MRI was more sensitive than
physical examination for detection of abnormalities in
multiple muscle groups [10, 11]. Yet, the rather slow dis-
ease progression in PD is one difficulty for MRI monitor-
ing of muscles changes. A retrospective study by Carlier et
al. using quantitative MRI demonstrated muscle fatty infil-
tration increase on average by 0.9%/year, with the ham-
string and adductor muscles showing the fastest
degradation. Muscle water T2 mapping revealed that 32%
of all muscles had abnormally high T2 in at least one of
two successive examinations. When muscle water T2 was
abnormal, fatty degenerative changes increased by 0.61%/
year. Enzyme replacement therapy resulted in 0.68%/year
slow-down of the muscle fatty infiltration, in both muscles
with normal and high T2s [12]. Unfortunately, most MRI
findings all indicate a rather late event in the course of the
disease, i.e., muscle atrophy. Furthermore, an overall slow-
down of muscle fatty infiltration of 0.68%/year may not
allow an individual prognosis, neither on the natural
course of the disease nor on the effectiveness of enzyme
replacement therapy. In addition, MRI imaging poses a
burden on patients with claustrophobia, is difficult to per-
form in patients with respiratory insufficiency in the su-
pine position and can be painful due to the long duration
of laying still on a hard bench.
Muscle biopsies using ultrastructural examination of the
tissue demonstrated reduced lysosomal glycogen after
6 months of ERT, consistent with stabilization of the dis-
ease that was not represented in the MRI images acquired
parallel to the biopsies [13]. However, muscle biopsies are
fraught due to (i) changing tissue localization at repeated
biopsies and (ii) the invasiveness of the procedure.
Thus, to date, none of the aforementioned methods
allow for a simple, reproducible measurement of disease
activity, localization of active disease and monitoring of
therapeutic efficacy.
Glucose and/or FDG uptake by the cell is a receptor-
mediated process. Glucose binds to the membrane bound
glucose-transporter (GLUT), as does FDG. The receptor-
ligand complex is taken up into the cell by endocytosis.
There the receptor separates from its substrate in early
endosomes and is passed on to recycling endosomes and,
subsequently, stored in the GLUT-containing vesicular
compartment. Once inside the cell, FDG is phosphory-
lated to FDG-6P, which cannot enter the glycolytic path-
ways and is therefore trapped within the cell (Fig. 1).
The mutation of acid α-glucosidase (GAA) gene leads
to reduced concentration/activity of the enzyme. This
results in a defective metabolism of lysosomal glycogen
with tissue-specific glycogen accumulation. We hypoth-
esized that the uptake of 2-deoxy-2-[18]fluoro-D-glu-
cose should lead to an accumulation of the labelled
glucose molecule in cells with pathological glycogen
storage. The extent of accumulation would indicate the
extent of glycogen storage, correlating with disease ac-
tivity and possible therapeutic efficacy. The method
would therefore allow for early detection of active foci
of glycogen deposits, well before fat accumulation or
muscle atrophy occurs.
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We therefore undertook an explorative study investi-
gating the usefulness of dynamic FDG-PET as an indica-
tor of disease activity in late-onset PD and compared
these results to routinely performed quantitative whole-
body muscle MRI.
Methods
We performed five FDG dynamic PET/CTs in four pa-
tients with late onset PD. In one patient, FDG-PET/CT
was performed twice, before and 1 year after the initi-
ation of ERT, while in all other patients FDG-PET/CT
took place during ongoing ERT. Patient characteristics
are given in Table 1.
FDG-PET Acquisition Dynamic FDG-PET allows to
quantify the metabolic rate of utilisation of glucose in
mg/ml/min. Patients were kept fasting for more than
6 h, and serum glucose was measured prior to the injec-
tion of FDG. Patients were given 350 MBq of FDG as
slow bolus over 20 s, and scanning was performed with
the patients supine. Dynamic images were acquired over
60 min in list-mode immediately after the injection of
the tracer. Images were reconstructed as follows: 3 ×
20 s, 8 × 30 s, 5 × 1 min, 5 × 2 min, 4 × 5 min and 2 ×
10 min. After the dynamic images, whole body images
were acquired from base of skull to mid-thigh with
1.5 min/bed position. Lean body mass maximum stan-
dardized uptake value (SUVmax) was calculated for in-
volved muscles; region of interest was drawn on the
muscles showing hyperintensity on MRI. In addition,
background activity was measured on the subcutaneous
fat at the level of gluteus muscle as well as over the left
ventricular cavity. For correction of the PET images, we
used a CT attenuation correction map.
MRI: standard T1w spin echo (SE) of the pelvis and
thigh muscles was performed (TR = 472 ms, TE = 18 ms)
and muscle fatty degenerative changes were scored ac-
cording to a 5-grade modified Mercuri score (grade 0:
normal, grade1: < 25%; grade 2: > 25% and < 50%; grade 3:
> 50% and < 75%; grade 4: > 75%). Short TI inversion re-
covery (STIR) sequences of the same body regions were
acquired with TR = 3240 ms, TE = 42 ms. Finally, after ad-
ministration of 0.1 mmol/kg of a gadolinium-based con-
trast agent (Gadovist; Bayer Healthcare), a T1w fat-sat
sequence was acquired (TR = 709 ms, TE = 18 ms). All
MR scans were acquired axially. For STIR and T1w fat-sat
contrast-enhanced (CE) images hyperintensities were
again scored according to a 5-grade modified Mercuri
score (grade 0: no hyperintensities, grade 1: mild; grade 2:
moderate; grade 3: intermediate; grade 4: severe amount
of hyperintensities). All MRIs were performed within
6 months of the FDG-PET. An experienced radiologist
(AP) analysed the MRI scans. Fatty infiltration as a marker
for muscular atrophy was scored based on T1w scans.
Hyperintensities in T1w FS CE and STIR scans show
hypervascularisation or leakage of contrast material and
oedema, respectively. The following pelvic and thigh mus-
cles were scored: autochthonous back muscle, iliopsoas,
gluteus maximus, medius and minimus (lateral, mid, med-
ial) quadriceps femoris, sartorius, obturator and pectineus.
Activity and atrophy on MRI were scored as follows: from
0 to 4 (0 = no atrophy; 1 =minimal, 2 =moderate, 4 =
Fig. 1 Scheme delineating cellular uptake of FDG
Table 1 Patients characteristics
Patient number 1 2 3 4
Age (years) 51 59 27 45
Years of ERT 1.5 6.5 7 0
Sex M M M M
Age at diagnosis (years) 50 45 20 44
Mutation c.(336-13 T > G);
(1927G > A)
IVC-45 T > G; 536bpDel
(IVS16 + 102_IVS17 + 31)
c.32-13 T > G;
c.1128_1129delinsC
c-32-13 T > G;
c.2214G > A
6-min walk test (m) 484 204 201 510
Wheelchair bound No No No No
Respiratory failure Yes Yes Yes No
aSD standard deviation
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severe). The FDG-uptake in the abovementioned muscles
was visually analysed. An example for the analysis of MRI
images is given in Fig. 2.
Statistics
Statistical analysis was performed using STATISTICA 6.0
and IBM SPSS Statistics (IBM, Armonk, NY), Version 21.
Data were calculated as median and interquartile range,
for correlation Spearman’s coefficient of correlation was
used. A p value < 0.05 was considered significant.
Results
Four male patients (median age 48, interquartile range
36–55 years) participated in this explorative study. All pa-
tients were on ERT. One patient was investigated twice,
before and after 1 year on ERT. All the patients demon-
strated clinical improvement compared to before ERT and
had either a stable (patients AB, FR) or slowly progressive
(patients GH, SK) course of their disease. Details of the
mutation and further clinical characteristics are indicated
in Table 1. Classification [14] of disease severity of was
moderate (one patient) and severe (three patients).
MRI fatty infiltration in T1w images as a sign for mus-
cular atrophy was found in all patients to varying degrees
and localizations (Table 2) and correlated well with the
clinical status of the patients. For all four patients, the
most atrophic muscles were the intrinsic back muscles
(autochthonous back muscles) and the gluteus muscles,
especially the gluteus minimus. Muscles with a high de-
gree of atrophy (score = 4) showed only low signal-
intensity in STIR and T1w FS CE images (score = 0–1;
score = 2 only in one case and muscle). When there was
no evidence of muscular atrophy (T1w score = 0), the
STIR and T1w FS CE images mostly also scored 0 in these
locations. However, in two patients there were muscles
without atrophic changes but with elevated STIR and T1w
FS CE values. Highest score for both STIR and T1w FS
CE were observed when muscular atrophy scores were be-
tween 1 and 3 (Fig. 3). Atrophy scores 0–2 positively cor-
related with T1w and STIR (Spearman’s R: 0.693, p < 0.05)
and T1w and T1w FS CE values (Spearman’s R: 0.644, p <
0.05). In contrast, atrophy scores 2-4 demonstrated a
negative correlation for T1w and STIR (Spearman’s R: −
0.426, p < 0.05) and for T1w and T1w FS CE, respectively
(Spearman’s R: − 0.334, p < 0.05). There was a strong posi-
tive correlation between STIR and T1w FS CE values
(Spearman’s R: 0.854, p < 0.05).
For all sequences, measured alterations were rather
symmetrically distributed (Spearman’s R for atrophy =
0.875, p < 0.05; activity = 0.829 p < 0.05; T1w FS CE =
0.92 p < 0.05).
Assuming an alpha error of 0.05, we receive an a pos-
teriori power of 1.000, 0.987 and 0.958 for T1, STIR and
T1FSCE, respectively.
Repeated MRI in one patient demonstrated a reduction
of the MRI scores at the tensor fasciae latae muscle after
1 year (Fig. 4). No other muscle group showed similar
improvements.
FDG-PET/CT. None of the muscles and/or regions of
muscles demonstrating hyperintensity on MRI showed a
quantifiable focally increased FDG metabolism. Nor did
we detect increased FDG-metabolism in trunk or thigh
muscles. Thus, dynamic PET quantification of glucose
metabolism in muscles could not be calculated. Figure 5
gives an example of the results of FDG-PET.
FDG-PET was positive in one patient with respiratory
failure. We observed a high uptake of FDG in the respira-
tory muscles. This clearly demonstrates the increased glu-
cose metabolism due to the high muscle workload in a
patient with restrictive respiratory insufficiency (Fig. 5).
Discussion
Our pilot study confirms the usefulness of MRI to delin-
eate affected muscles in PD [9, 12, 14–16]. The pattern
of involvement was similar in patients with and without
ERT [14] and disease severity and duration were corre-
lated to quantitative MRI findings.
We analysed 26 different muscle regions of the pelvis and
thighs in four different patients with late onset PD. Within
individual patients, there were considerable differences in
Fig. 2 MR scans of a Pompe patient at the level just below the pelvic floor. There are different stages of muscular inflammation, or atrophy
respectively, visible: T1w images show fatty atrophy in various muscles, pronounced in the middle part of the gluteus maximus (a, arrow head).
The medial part of the gluteus maximus shows only beginning atrophy at T1w (a, arrow) together with high signal in the STIR images (b). T1w FS
scans also display high signal after gadolinium administration (c). While the tensor fasciae latae muscle (wide arrow) seems to be unaffected in
the T1w images, there is high signal on STIR and T1w FS scans suggesting early changes
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muscular atrophy of different muscles ranging from no vis-
ible atrophy (score = 0) to severe atrophy (score = 4) with
the intrinsic back muscles and the gluteus minimus muscle
displaying the highest scores of atrophy. We found no ob-
servable atrophy in the quadriceps femoris (rectus femoris)
and sartorius muscle. Why these muscles display minor
damage while others are heavily involved is a matter of de-
bate and was also observed in earlier studies [13, 15]. Van
der Ploeg et al. [13] suggests that muscle groups, like the
gluteus muscles and intrinsic back muscles, performing
continuous or repetitive contraction are more prone to
earlier damage than muscles that are subject to relatively
intermittent contraction.
STIR images revealing muscular oedema were only
partly in line with the results of the T1w images showing
atrophy: when muscular atrophy was not visible (score =
0) in most of the muscles analysed there was also no
oedema. Oedematous changes increased with increasing
atrophy, but only up to an atrophy score of 2–3 (correl-
ation of Spearman’s R: 0.693). When atrophy was more
prevalent (score 4) oedematous changes decreased (Spear-
man’s R: − 0.426). None of the T1w changes with a score
of 4 showed an oedema score higher than 2. As a rule,
similar changes as for the STIR images were noted for the
T1w FS CE images in most of the muscles analysed.
The varying degree of atrophy and oedema/inflamma-
tion in different muscles in a given individual with
PD—besides the already mentioned predilection of certain
muscles—indicates a temporal heterogeneity of muscular
changes. We hypothesize that disease manifestation in a
muscle initially demonstrates only little atrophy but an in-
creasing amount of oedema and inflammatory changes as
reflected by increased STIR and T1w FS CE values. Of
note, in some muscles, oedematous and inflammatory
changes were visible in muscles showing no atrophy at all,
consistent with results by van der Ploeg et al. [13].
After this initial stage, atrophic, oedematous and in-
flammatory changes seem to develop rather synchron-
ously up to the point when inflammation and oedema
are less visible, but atrophy further increases. Finally, at













Intrinsic back muscles (lower back) 3.0 3.0–3.0 0.0 0.0–3.0 0.0 0.0–3.0
Iliopsoas 2.0 0.5–3.5 1.0 0.0–2.5 1.5 0.0–2.5
Gluteus maximus (lateral) 2.0 0.5–4.0 1.0 0.0–2.0 1.5 0.5–2.0
Gluteus maximus (center) 0.0 0.0–1.5 0.0 0.0–1.5 0.0 0.0–1.5
Gluteus maximus (medial) 1.5 0.0–3.0 1.0 0.0–2.0 1.0 0.0–2.5
Gluteus medius (ventral) 2.0 1.0–3.5 1.5 1.0–2.0 2.0 1.0–3.5
Gluteus medius (dorsal) 3.5 1.5–4.0 1.0 0.0–1.5 0.5 0.0–1.5
Gluteus minimus (ventral) 4.0 3.5–4.0 0.5 0.0–1.5 0.5 0.0–1.5
Gluteus minimus (dorsal) 4.0 3.5–4.0 0.5 0.0–1.5 0.5 0.0–1.5
Rectus femoris 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–0.0
Sartorius 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–0.0
Obturator ext. 1.0 0.5–2.0 0.0 0.0–0.5 0.0 0.0–0.5
Pectineus 0.0 0.0–2.5 0.0 0.0–0.0 0.0 0.0–0.0
aInterquartile range
T1 images were scored according to a 5-grade score (grade 0: normal, grade 1: < 25%; grade 2: > 25% and < 50%; grade 3: > 50% and < 75%; grade 4: > 75%). STIR
and T1w fat-sat contrast-enhanced (CE) images were scored according to a 5-grade score (grade 0: no hyperintensities, grade1: mild; grade 2: moderate; grade 3:
intermediate; grade 4: severe amount of hyperintensities)
Fig. 3 Scatterplot between the semi-quantitative assessment of T1
(atrophy) and STIR (muscle oedema): the size of the circle displays
the number of muscle regions. Most muscle regions showed no
atrophy (T1 = 0) and no oedema (STIR = 0). As atrophy increases so
does muscular oedema, but only up to a score of T1 = 2. From there,
further atrophy is associated with less oedema. Of note, some
muscles showing no atrophy (T1 = 0) already exhibited oedema,
possibly an early sign of affected muscle
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Fig. 4 a Maximum intensity projection image showing the paravertebral brown fat as well as intercostal muscle. b Upper panel showing fused
FDG PET/CT image with gluteus muscle atrophy and almost no FDG-uptake (white arrows). c Lower panel showing paravertebral and axillary
brown fat (open arrows)
Fig. 5 MRI (a, b) and FDG PET (c, d) before and after 1 year of ERT. MRI shows slight improvement, i.e., less hyperintensity of the tensor fasciae
latae muscle (arrow) in the T1w sequence after gadolinium administration 1 year after ERT. FDG-PET show no significantly different tracer uptake
in the region of interest (orange and blue lines) pre- and post-therapy
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the end-stage of this process affected muscles display
fatty infiltration as a result of atrophy but no more in-
flammation or oedema.
This study is the first study that used gadolinium-
enhanced MR imaging for the evaluation of non-cardiac
muscle involvement in late-onset PD patients. Gadolinium-
based studies have shown benefits in other forms of myo-
sitis for differentiation and staging [17]. In the present
study, we found a strong positive correlation between STIR
and T1 FS CE images (R = 0.854). However, there was one
significant difference between the STIR and T1 FS CE im-
ages, with the gadolinium-based T1 images showing higher
values on the modified Mercuri scale. This may indicate
that T1 FS CE might be more sensitive to early muscle
changes in late-onset PD patients. If gadolinium studies are
really necessary for early detection needs to be evaluated in
further studies, especially in light of the problem of gadolin-
ium deposition that was first described in 2014 [18].
Due to MRI limitations (claustrophobia, non-MRI com-
patible devices, severe respiratory disease) [10], alternative
approaches like bio-impedance measurement to assess the
relative proportions of fatty and muscle tissue may give a
correlation between the degree of replacement of the
muscle tissue with fatty tissue and the severity of the dis-
ease evaluated clinically [19], diagnosing the late phase of
the disease.
In conclusion, MRI is an excellent tool to demonstrate
the extent of muscle involvement in late-onset PD. MRI
may even pick up early, i.e., oedematous stages of the
disease. Focusing on these early signs may allow more
specific training early on to set against subsequent mus-
cular atrophy. Whether these early changes may allow
prognostic predictions has yet to be demonstrated.
In well-prepared (after 6-h fast, serum glucose <
150 mg/dl and adequate rest prior to image acquisition)
non-PD patients no or only faint muscular FDG uptake
can be observed. We hypothesized that in PD FDG-
PET/CT would delineate increased accumulation of glu-
cose into glycogen-enriched depots and thus diagnose
the early phases of the disease. In α-glucosidase-
deficient muscles lysosomal glycogen breakdown and
thus glucose and energy production are reduced. To
compensate for reduced glucose production, increased
glucose and in analogy FDG uptake may be an option in
these cells. In α-glucosidase-deficient muscles intra-
cytoplasmatic GLUT4 expression is increased in dam-
aged and normal in unafflicted muscle fibres [20]. We
hypothesized that this increased GLUT4 expression may
correlate with an increased glucose and thus an in-
creased FDG uptake as well.
This information may then translate in improved local
physiotherapy and/or anti-inflammatory treatment. Un-
fortunately, no focally increased FDG accumulation in
relation or unrelated to MRI-signal changes could be
demonstrated. Thus, dynamic PET quantification of
glycogen deposition in muscles could not be calculated.
There might be multiple explanations for this result. Nu-
tritional status, i.e., fasting or post-prandial application
of the tracer may be an issue. We injected FDG in fast-
ing patients and thus glycolysis may have prevailed
glycogenesis. This is in line with our observation of an
increased uptake in the respiratory muscles in the pa-
tient with severe restrictive respiratory failure. Due to
the high workload of respiratory muscles glucose metab-
olism was increased as it was visualized in the FDG
PET/CT. Again, this would indicate a rather late state of
the disease, as the increased metabolic needs are corre-
lated with a significantly increased workload on the few
remaining/surviving muscles. On the other hand, with
the patient supine, the energy requirement of all other
muscles was low and therefore no increased glucose me-
tabolism could be observed.
In addition, glucose uptake via GLUT4 occurs either
post-prandially insulin-stimulated or during exercise
[21]. However, all patients were investigated after an
overnight resting phase without increased muscular en-
ergy needs. Whether post-exercise FDG may have given
different results, remains to be investigated.
Alternatively, deposition of the tracer into glycogen
may not have taken place at all. Glycogen is synthesized
from the activated glucose-donor, uridine diphosphate
glucose (UDP-glucose), catalysed by glycogen synthase,
the key regulatory enzyme in glycogenesis. To be incor-
porated into glycogen, FDG has to be modified by
glucose-6-phosphate isomerase which catalyses the sec-
ond step during glycolysis. It has been suggested that the
substitution of the C-2 hydroxyl moiety by 18F prevents
this process [22]. Subsequently, FDG could possibly not
be integrated into glycogen. A new tracer, 18F-N-(me-
thyl-(2-fluoroethyl)-1H-[1,2,3]triazole-4-yl) glucosamine
(18F-NFTG), recently developed, may be a more effective
biomarker in PD. So far, 18F-NFTG PET has been used
in animal tumour models to visualize tumours of the
upper thorax where the rate of glycogen synthesis is
cell-cycle regulated and enhanced during the non-
proliferating stage of cancer cells [22]. Whether the my-
opathy of PD is a feasible target for integrating this new
tracer for demonstrating early glycogen accumulation re-
mains to be demonstrated.
Conclusions
In conclusion, MRI delineated the localisation and ex-
tent of muscle atrophy in all patients. Changes in the
STIR and gadolinium-based T1w sequences probably
show the activity of the disease and can serve as earlier
markers in the disease process than late changes re-
vealed by fatty infiltration of atrophic muscles as mea-
sured by T1-weighted sequences.
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FDG PET/CT did not demonstrate increased up-
take in glycogen, neither in the early nor late phase
of the tracer accumulation. A positive signal was de-
tected by FDG PET/CT in the patient with respira-
tory failure. Due to the increased respiratory muscle
workload, glucose utilisation and thus FDG-uptake
was increased as well.
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SD: Standard deviation; SE: Spin echo; STIR: Short TI inversion recovery;
T1: T1-weighted image; TE: Echo time; TI: Inversion time; TR: Repetition time;
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